Literature DB >> 25066382

Training should be the first step toward an antifungal stewardship program.

Maricela Valerio1, Patricia Muñoz2, Carmen Rodríguez-González3, María Sanjurjo3, Jesús Guinea4, Emilio Bouza2.   

Abstract

The frequency of use of systemic antifungal agents has increased significantly in most tertiary centers. However, antifungal stewardship has received very little attention. The objective of this article was to assess the knowledge of prescribing physicians in our institution as a first step in the development of an antifungal stewardship program. Attending physicians from the departments that prescribe most antifungals were invited to complete a questionnaire based on current guidelines on diagnosis and therapy of invasive candidiasis and invasive aspergillosis (IA). The survey was completed by 60.8% (200/329) of the physicians who were invited to participate. The physicians belonged to the following departments: medical (60%), pediatric (19%), intensive care (15.5%), and surgical (5.5%). The mean (±SD) score of correct responses was 5.16±1.73. In the case of candidiasis, only 55% of the physicians clearly distinguished between colonization and infection, and 17.5% knew the local rate of fluconazole resistance. Thirty-three percent knew the accepted indications for antifungal prophylaxis, and 23% the indications for empirical therapy. However, most physicians knew which antifungals to choose when starting empirical therapy (73.5%). As for aspergillosis, most physicians (67%) could differentiate between colonization and infection, and 34.5% knew the diagnostic value of galactomannan. The radiological features of IA were well recognized by 64%, but only 31.5% were aware of the first line of treatment for IA, and 36% of the recommended duration of therapy. The usefulness of antifungal levels was known by 67%. This simple, easily completed questionnaire enabled us to identify which areas of our training strategy could be improved.
Copyright © 2013 Elsevier España, S.L.U. y Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. All rights reserved.

Entities:  

Keywords:  Antifungal stewardship; Antifungal use; Aspergilosis invasiva; Candinas; Candins; Control de antifúngicos; Fluconazol; Fluconazole; Invasive aspergillosis; Uso de antifúngicos

Mesh:

Substances:

Year:  2014        PMID: 25066382     DOI: 10.1016/j.eimc.2014.04.016

Source DB:  PubMed          Journal:  Enferm Infecc Microbiol Clin        ISSN: 0213-005X            Impact factor:   1.731


  6 in total

Review 1.  The Role of Diagnostics-Driven Antifungal Stewardship in the Management of Invasive Fungal Infections: A Systematic Literature Review.

Authors:  Arunaloke Chakrabarti; Naglaa Mohamed; Maria Rita Capparella; Andy Townsend; Anita H Sung; Renee Yura; Patricia Muñoz
Journal:  Open Forum Infect Dis       Date:  2022-05-11       Impact factor: 4.423

2.  Infection prevention requirements for the medical care of immunosuppressed patients: recommendations of the Commission for Hospital Hygiene and Infection Prevention (KRINKO) at the Robert Koch Institute.

Authors: 
Journal:  GMS Hyg Infect Control       Date:  2022-04-13

3.  Management of Invasive Fungal Infections in Adult Patients with Hematological Malignancies in Greece during the Financial Crisis: Challenges and Recommendations.

Authors:  Nikolaos V Sipsas; Maria N Pagoni; Diamantis P Kofteridis; Joseph Meletiadis; Georgia Vrioni; Maria Papaioannou; Anastasia Antoniadou; George Petrikkos; George Samonis
Journal:  J Fungi (Basel)       Date:  2018-08-09

4.  Efficacy of a "Checklist" Intervention Bundle on the Clinical Outcome of Patients with Candida Bloodstream Infections: A Quasi-Experimental Pre-Post Study.

Authors:  Antonio Vena; Emilio Bouza; Rafael Corisco; Marina Machado; Maricela Valerio; Carlos Sánchez; Patricia Muñoz
Journal:  Infect Dis Ther       Date:  2020-02-04

5.  Evaluation of a stewardship program of antifungal use at a Brazilian tertiary care hospital.

Authors:  Fabiola Gamarra; Marcio Nucci; Simone A Nouér
Journal:  Braz J Infect Dis       Date:  2022-02-16       Impact factor: 3.257

6. 

Authors: 
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2021-02       Impact factor: 1.513

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.